Rule on Attorney-Client Privilege for Trials Before the Patent Trial and Appeal Board, 51570-51575 [2017-24190]
Download as PDF
51570
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
risk of cardiovascular diseases; for use
in diabetes management; for identifying
or inferring the identity of a
microorganism directly from clinical
material; for detection of antibodies to
microorganisms other than
immunoglobulin G (IgG) and IgG assays
when the results are not qualitative, or
are used to determine immunity, or the
assay is intended for use in matrices
other than serum or plasma; for
noninvasive testing; or for near-patient
testing (point of care).
Exemption from the requirement of
premarket notification does not exempt
a device from other applicable
regulatory controls under the FD&C Act,
including the applicable general and
special controls. Indeed, FDA’s decision
to grant 510(k) exemption for these
devices is based, in part, on the special
controls, in combination with general
controls, providing sufficiently rigorous
mitigations for the risks identified for
this generic type.
This exemption from 510(k), subject
to the limitations described above, is
immediately in effect for autosomal
recessive carrier screening gene
mutation detection systems. This
exemption will decrease regulatory
burdens on the medical device industry
and will eliminate private costs and
expenditures required to comply with
Federal regulation. Specifically,
regulated industry will no longer have
to invest time and resources in
premarket notifications, including
preparation of documents and data for
submission to FDA, payment of user
fees associated with 510(k) submissions,
and responding to questions and
requests for additional information from
FDA during 510(k) review for devices in
this exempted type.
nshattuck on DSK9F9SC42PROD with RULES
VII. Analysis of Environmental Impact
We have determined under 21 CFR
25.34(b) that this action is of a type that
does not individually or cumulatively
have a significant effect on the human
environment. Therefore, neither an
environmental assessment nor an
environmental impact statement is
required.
VIII. Paperwork Reduction Act of 1995
This notice refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 807, subpart, E have been
approved under OMB control number
0910–0120 and the collections of
information in 21 CFR parts 801 and
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
809 have been approved under OMB
control number 0910–0485.
IX. References
Dated: November 1, 2017.
Lauren Silvis,
Chief of Staff.
[FR Doc. 2017–24162 Filed 11–6–17; 8:45 am]
The following references are on
display in the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; they are also available
electronically at https://
www.regulations.gov. FDA has verified
the Web site addresses, as of the date
this document publishes in the Federal
Register, but Web sites are subject to
change over time.
BILLING CODE 4164–01–P
1. FDA Guidance, ‘‘Procedures for Class II
Device Exemptions from Premarket
Notification, Guidance for Industry and
CDRH Staff,’’ February 19, 1998,
available at https://www.fda.gov/
downloads/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/UCM080199.pdf.
2. FDA Guidance for Industry and FDA Staff
‘‘Class II Special Controls Guidance
Document: CFTR Gene Mutation
Detection Systems,’’ October 26, 2005,
available at: https://www.fda.gov/
downloads/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/ucm071104.pdf.
Rule on Attorney-Client Privilege for
Trials Before the Patent Trial and
Appeal Board
List of Subjects in 21 CFR Part 866
Biologics, Laboratories, Medical
devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 866 is
amended as follows:
PART 866—IMMUNOLOGY AND
MICROBIOLOGY DEVICES
1. The authority citation for part 866
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
2. In § 866.5940, revise paragraph (b)
introductory text to read as follows:
■
§ 866.5940 Autosomal recessive carrier
screening gene mutation detection system.
*
*
*
*
*
(b) Classification. Class II (special
controls). The device is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 866.9,
except § 866.9(c)(2). Autosomal
recessive carrier screening gene
mutation detection system must comply
with the following special controls:
*
*
*
*
*
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
37 CFR Part 42
[Docket No. PTO–P–2016–0029]
RIN 0651–AD10
Patent Trial and Appeal Board,
United States Patent and Trademark
Office, U.S. Department of Commerce.
ACTION: Final rule.
AGENCY:
This final rule on attorneyclient privilege amends the existing
rules relating to the United States Patent
and Trademark Office (Office or
USPTO) trial practice for inter partes
review, post-grant review, the
transitional program for covered
business method patents, and derivation
proceedings that implemented
provisions of the Leahy-Smith America
Invents Act (‘‘AIA’’) providing for trials
before the Office.
DATES: This rule is effective on
December 7, 2017.
FOR FURTHER INFORMATION CONTACT:
Edward Elliott, Attorney Advisor, by
telephone at (571) 272–7024 or by email
at edward.elliott@uspto.gov.
SUPPLEMENTARY INFORMATION:
Executive Summary: Purpose: This
final rule clarifies situations where
privilege is recognized for
communications between clients and
their domestic or foreign patent
attorneys and patent agents.
SUMMARY:
Background
In February 2015, the USPTO held a
roundtable and solicited comments on
attorney-client privilege issues. See
Notice of Roundtable and Request for
Comments on Domestic and
International Issues Related to
Privileged Communications Between
Patent Practitioners and Their Clients,
80 FR 3953 (Jan. 26, 2015). As part of
that process, the USPTO requested
comments on whether communications
between patent applicants or owners
with their U.S. patent agents or foreign
patent practitioners should be
recognized as privileged to the same
E:\FR\FM\07NOR1.SGM
07NOR1
nshattuck on DSK9F9SC42PROD with RULES
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
extent as communications with U.S.
patent attorneys. Respondents
unanimously supported a rule
recognizing such privilege in courts. See
USPTO, Summary of Roundtable and
Written Comments, available at https://
www.uspto.gov/sites/default/files/
documents/Summary%20of%
20Privileged%20Communication%20
Roundtable.pdf (‘‘Privilege Report’’).
Some roundtable participants noted
that rules regarding privilege for U.S.
patent agents and foreign practitioners
in PTAB discovery proceedings were
difficult to discern, as there has been no
explicit rule on privilege. When the
issue arises before PTAB,
Administrative Law Judges make legal
determinations as to which
communications may be protected from
disclosure on a case-by-case basis, based
on the Federal Rules of Evidence and
common law. See 37 CFR 42.62(a); see
also GEA Process Engineering, Inc. v.
Steuben Foods, Inc., IPR2014–00041,
Paper 117 (PTAB 2014). U.S. courts
have devised several different
approaches to determine under what
circumstances communications with
these practitioners are privileged. As the
Privilege Report notes, the common law
on privilege for domestic and foreign
patent practitioners varies across
jurisdictions. Different approaches are
taken, and results sometimes conflict.
This may lead to administrative
inefficiencies and inconsistencies in
outcomes, as PTAB must select which
set of common law rules to follow.
Administrative Law Judges in other
agencies have treated certain
confidential communications with a
patent agent as privileged. See, e.g.,
USITC Inv. No. 337–TA–339, slip op. at
2, 1992 WL 811804 (ITC 1992) (finding
that confidential communications
between a U.S. patent agent and his
client in connection with a patent
prosecution are privileged). In 2016, the
Federal Circuit recognized that attorneyclient privilege applies to U.S. patent
agents acting within the scope of their
authorized practice. See In re Queen’s
University at Kingston, 820 F.3d 1287
(Fed. Cir. 2016).
To address the aforementioned issues
with privilege rules, the USPTO put
forth a proposed PTAB rule for public
comment in October 2016. See Rule
Recognizing Privileged Communications
Between Clients and Patent
Practitioners at the Patent Trial and
Appeal Board, 81 FR 71653 (Oct. 18,
2016). The Office received eighteen
comments from bar associations, trade
groups, law firms, and individuals. The
Office expresses its gratitude for the
thoughtful and comprehensive
comments provided by the public,
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
which are available online at https://
www.regulations.gov/docket?D=PTO-P2016-0029.
The vast majority of commenters
expressed support for this rule, echoing
the need for clarity and certainty in this
area. The policy arguments they raised
in favor are already covered extensively
in the Privilege Report. Several
commenters raised additional issues
about specific language in the proposed
rule, which are addressed herein. A few
commenters opposed the rule based on
misunderstandings of the scope and
purpose of the rule, which are clarified
herein as well. Based on the feedback,
the Office presents the following final
rule on recognizing privilege for patent
attorneys and agents.
Responses to Comments
Nature of Privilege
Comments: Some comments
expressed concern over the scope and
interpretation of the proposed rule. One
commenter objected to expanding those
eligible to practice before PTAB to
include agents. Others characterized the
rule as primarily to protect
communications between clients and
counsel involved in PTAB proceedings.
Response: Attorney-client privilege
exists to protect clients. It allows them
to have full and frank discussions with
attorneys when seeking legal advice,
without fear that those discussions will
be used against them in legal
proceedings. The privilege vests with
the client, not the attorney, and does not
confer authorization to practice law, but
rather flows from those already having
such authorization. Because of this,
recognizing privilege for patent agents
does not determine what types of work
they are authorized to perform. The
authorized functions of patents agents,
including representing clients before
PTAB, are established in 37 CFR 11.5(b).
Likewise, privilege does not confer
additional power to patent agents
because it vests in the client, not the
agent or attorney. Applying the privilege
to agents simply recognizes that they
perform legal services and that clients
deserve the same protections regardless
of which type of authorized legal
provider they choose. Further, some
foreign jurisdictions rely entirely or
almost entirely on non-attorney patent
agents. In such jurisdictions, hiring an
attorney to handle patent matters can be
difficult or impossible. See the Privilege
Report for further discussion of the
policy considerations supporting
privilege for patent agents.
More fundamentally, this rule is not
intended primarily to protect
communications between clients and
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
51571
their counsel for purposes of PTAB
proceedings. Rather, it is primarily
intended to protect communications
made when seeking patents at the
USPTO or foreign IP offices, such as
when prosecuting applications or
contemplating whether to file. The
counsel on those communications may
not be involved in any PTAB
proceedings. Communications about
prosecution are much more commonly
implicated in PTAB discovery
proceedings than communications about
the PTAB proceeding itself. Perhaps this
reflects the inherent asymmetry of
privilege protections: Both parties are
affected if their communications seeking
legal advice about the PTAB proceeding
are discoverable, whereas only the
patent holder is affected by discovery of
communications from prosecution.
Regardless, the purpose of the rule is to
protect any communications with
authorized counsel from discovery in
PTAB, not just communications about
the instant proceeding.
Similarly, this privilege rule does not
affect an attorney, agent, or applicant’s
duty to disclose material information to
the USPTO at any time, as the duty of
disclosure under 37 CFR 1.56 continues
to be controlling. This duty is not at
odds with privilege protections; the
duty of disclosure governs all
information known by a party and
establishes whether information must be
provided to the USPTO, while privilege
governs material available to third party
adversaries in adjudicated proceedings
under part 42. For instance, the
privilege rule does not apply in the
filing and prosecution of a patent
application. Further, the privilege only
protects information exchanged for
purposes of obtaining legal opinions or
services, not underlying facts or
business documents. The precise metes
and bounds of what types of
communications are protected by
privilege are determined according to
Federal law. Finally, this rule does not
nullify privilege for others who are not
covered by the rule, such as attorneys
not admitted to practice before the
USPTO or a foreign patent office. Other
sources of privilege under Federal law
remain unaffected.
Scope of Activities
Comments: Some commenters
requested clarity on the scope of
covered activities. One commenter
asked the USPTO to clarify whether a
communication with a registered patent
agent about claim interpretation of an
issued patent would qualify as
privileged. Others asked for general
clarification of what activities by patent
agents would be covered, with one
E:\FR\FM\07NOR1.SGM
07NOR1
51572
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
requesting examples of activities that
would qualify for the privilege. One
commenter noted that 37 CFR 11.5(b)(1)
may not provide an exhaustive list of
authorized activities.
Response: We understand the
commenters’ desire for clarity on these
issues. The USPTO has described the
functions agents are authorized to
perform before the Office in 37 CFR
11.5(b)(1). Whether a particular scenario
falls within the bounds of an agent’s
authorization is subject to determination
by an appropriate authority.
More precisely defining what types of
work patent agents are and are not
authorized to perform is a much larger
issue that goes far beyond privilege
considerations. This rulemaking is not
the proper forum to address that issue.
If the public feels that the general
definition of authorized functions put
forth by the USPTO in § 11.5(b)(1)
should be updated, they should contact
the USPTO to express interest in a more
comprehensive process to consider that
issue, which accounts for the numerous
equities involved. We also note that
regardless of any clarifications made to
the scope of authorized duties for U.S.
patent agents, the USPTO cannot alter
or clarify the authorized functions of
foreign patent agents in their home
jurisdiction, which are established by
foreign laws and regulations.
nshattuck on DSK9F9SC42PROD with RULES
Federal Privilege
Comments: One comment suggested
clarifying that the ‘‘same protections of
privilege’’ refers to Federal privilege,
since state courts have their own
separate sources of privilege.
Response: We concur and have
adjusted the rule to specify ‘‘privilege
under Federal law’’ in paragraph (a).
Direct Communications
Comments: One comment suggested
that the rule as written may only cover
communications directly between a
client and a foreign practitioner, and not
communications made by the client’s
U.S. attorney with the foreign
practitioner. According to the comment,
communications made between a
client’s representatives in the absence of
the client could be inadvertently
excluded by the current phrasing of the
rule.
Response: Under U.S. Federal law,
attorney-client privilege generally
encompasses communications with an
attorney made by the client’s
representatives as well as the client.
Similarly, privilege generally
encompasses communications made
with an attorney’s employee or
assistant, as well as communications
between multiple attorneys working for
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
a client. That is not to say such
communications are necessarily
privileged; they must still meet the
other requirements for privilege, such as
appropriate subject matter. However,
these parties are generally regarded as
parties that fall within the scope of
privilege, rather than as third parties
who break privilege.
Under the new rule, communications
with such parties should similarly be
entitled to privilege under the same
circumstances as when the practitioner
is an attorney. However, we recognize
that there is potential for a narrower
reading of the proposed rule that does
not cover communications with such
parties and therefore affords lesser
protection to non-attorney practitioners.
We have added paragraph (c) to the rule
to clarify that the scope of coverage will
be the same for practitioners as for
attorneys under these types of scenarios
and any other situations. For instance,
privilege will extend to communications
with the aforementioned parties under
appropriate circumstances, not just to
communications directly between the
practitioner and the client.
Limitations and Exceptions
Comments: One comment suggested
explicitly defining which ‘‘limitations
and exceptions’’ should apply to the
privilege.
Response: Exceptions to attorneyclient privilege such as crime/fraud are
based on longstanding common law,
which continues to evolve. Our purpose
here is not to redefine those exceptions.
This may lead to growing discrepancies
as the common law changes, which
could lead to disparate treatment of
privilege for patent attorneys and agents
compared with other attorneys. Rather,
this rule codifies who is eligible for the
privilege, while leaving questions about
exceptions and limitations for general
jurisprudence to address in a broader
manner.
Practitioners With Limited Recognition
Comments: A couple of commenters
noted that the rule does not extend to
all categories of practitioners, namely,
those granted limited recognition under
37 CFR 11.9.
Response: The rule has been amended
to cover USPTO practitioners meeting
the registration requirements of 37 CFR
11.7. This includes practitioners under
both §§ 11.6 and 11.9(b), who have
demonstrated the requisite legal,
scientific, and technical qualifications
and moral character. Foreign
practitioners practicing at the USPTO
under § 11.9(c) can qualify for privilege
under paragraph (b) of the new rule
through their admittance to practice in
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
a foreign jurisdiction. Students in the
USPTO law school clinic program
practicing under § 11.16 can qualify for
privilege under paragraph (c) of the new
rule since they work under the
supervision of a registered practitioner.
At this time, we are not convinced an
extension to other categories of
practitioners is necessary or
appropriate. It is not clear that
recognizing privilege for these
individuals furthers any of the policy
reasons for applying privilege to patent
agents, or that these individuals play a
significant role in providing legal
services for applicants.
Relation to In re Queen’s
Comments: A few commenters noted
the parallels between this rule and the
Federal Circuit’s decision in In re
Queen’s University, wondering if a
USPTO rule is still necessary and
whether there would be any distinction
between our rule and the Federal
Circuit’s. One commenter mentioned a
supposed difference in coverage for
third-party patent validity opinions by
agents.
Response: The USPTO supports the
Federal Circuit’s finding of privilege for
patent agents as a matter of public
policy. The Privilege Report catalogs the
many reasons that privilege for patent
agents is warranted. A USPTO rule on
privilege is still needed, for at least
several reasons. The Queen’s decision
was a 2–1 panel result, which may be
revisited in future cases either en banc
at the Federal Circuit or at the Supreme
Court. There are clarity benefits to
having a rule explicitly codified rather
than only in common law.
Also, the Federal Circuit decision
only addresses domestic patent agents,
not foreign attorneys and agents.
Without comparable protections in U.S.
tribunals for foreign practitioners,
privileged communications with U.S.
patent attorneys may effectively lose
that protection through parallel
communications with foreign
practitioners prosecuting corresponding
foreign applications, which often raise
very similar legal issues. Having a U.S.
attorney supervise communications
with foreign practitioners is not only an
undesirable policy, but may not be
enough to preserve privilege in all
circumstances. Because the U.S.
attorney is generally not authorized to
practice law in foreign jurisdictions, the
foreign attorney might not be considered
as working ‘‘under the supervision’’ of
the U.S. attorney in all instances.
Further, some jurisdictions use nonattorney patent agents exclusively or
predominantly, so it may not be
possible for applicants to rely on
E:\FR\FM\07NOR1.SGM
07NOR1
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
nshattuck on DSK9F9SC42PROD with RULES
privilege afforded by U.S. courts to
foreign attorneys. The new privilege
rule protects eligible communications
with qualified foreign attorneys and
agents from discovery at PTAB,
preventing such back door exposure.
The rule does not have extraterritorial
effects; how communications with U.S.
and foreign practitioners are treated by
foreign courts is entirely up to the
foreign jurisdiction.
Another reason for the USPTO’s rule
is administrative economy and judicial
efficiency, as explained by commenter
John Cross of the University of
Louisville. The typical approach to
privilege for foreign practitioners
examines whether the foreign
jurisdiction affords something like
privilege for attorneys and agents.
However, this inquiry can be intensive,
difficult, and lead to inconsistent
results, because many jurisdictions do
not need a comparable protection when
their constrained discovery system
prevents communications with patent
practitioners from even being
discoverable. Similarly, U.S. courts that
use a ‘‘touch base’’ standard often make
complex inquiries into a foreign
communication’s nexus with the United
States, which can lead to uncertain and
inconsistent results. The USPTO rule
simplifies such inquiries by instead
considering whether the foreign
practitioner was authorized to practice
within their home jurisdiction by
satisfying their jurisdiction’s
professional requirements, and whether
the communications fall within their
authorized scope of practice in that
jurisdiction. These criteria are simpler
to adjudicate and lead to more
predictable and consistent results,
helping applicants understand where
privilege applies long before they
appear at a tribunal.
Also, the USPTO rule applies
regardless of the source of privilege for
agents. Whether there is a separate
agent-client privilege or agents are
afforded attorney-client privilege on the
basis of practicing patent law does not
matter for purposes of this rule. The rule
simply recognizes that privilege issues
will be treated the same for agents as for
attorneys within their scope of
authorized practice.
Practice of Law
Comments: Two commenters
suggested that the rule would promote
the ‘‘unauthorized practice of law’’ by
U.S. patent agents. It was suggested that
participation by patent agents in PTAB
proceedings would constitute
unauthorized practice, and that agents
participating in PTAB proceedings held
concurrently with patent litigation on
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
the same patents would constitute
unauthorized litigation practice by those
agents. One of these commenters also
said that state bar rules may conflict
with this PTAB rule.
Response: As previously mentioned,
the rule does not grant additional
powers to patent agents. Privilege is a
protection that vests with the client, not
the practitioner. Agents are already
authorized to practice before PTAB in
any USPTO proceedings. Practice before
PTAB cannot be unauthorized practice
of law because U.S. patent agents are
authorized to do so.
The second objection suggests that
practicing before PTAB is tantamount to
practicing before Federal courts when
there is concurrent litigation on the
same patents. Because they are separate
venues with separate practices and
practitioners, this argument is not
persuasive. Agents are authorized to
advise and represent clients in PTAB
proceedings because the issues are
restricted to patent law matters they are
authorized to perform. Federal courts
have different jurisdiction than PTAB
and consider a range of non-patent
issues. The fact that certain patent
issues, such as validity, may arise before
both tribunals does not equate practice
before both venues. Just because a
practitioner is authorized to address the
issue in one forum does not mean they
are authorized to address it in other
forums. This is true regardless of
whether the practitioner is an agent or
an attorney and whether the two forums
are, for instance, PTAB and a Federal
court, or a Federal court and a foreign
court.
Finally, state bar rules generally are
not germane to USPTO rules. The
USPTO may properly regulate the
conduct of practitioners before the
Office, including PTAB proceedings, as
authorized by Congress. Similarly, states
can properly regulate the practice of law
within their borders, subject to
federalism principles and rules
established by the Supreme Court. The
USPTO and states have separate
jurisdiction. States may of course
consider the policy issues the USPTO
has documented when deciding
privilege matters within their own
courts for domestic and foreign patent
agents and attorneys.
Changes From the Proposed Rule
In response to comments received
from the public, the USPTO makes the
following changes from the proposed
rule. The terms for types of practitioners
(domestic and foreign) were adjusted
slightly for uniformity with other rules.
The application of Federal law was
clarified. The USPTO registration
PO 00000
Frm 00025
Fmt 4700
Sfmt 4700
51573
requirement now points to 37 CFR 11.7
for more precision. Paragraph (c) was
added to clarify that non-attorney
practitioners are afforded privilege in all
the same situations as attorneys, not just
for direct communications between
practitioner and client.
Rulemaking Considerations
A. Administrative Procedure Act
(APA): This final rule revises the rules
relating to Office trial practice for inter
partes review, post-grant review, the
transitional program for covered
business method patents, and derivation
proceedings. The changes being adopted
in this notice do not change the
substantive criteria of patentability.
These changes involve rules of agency
practice. See, e.g., 35 U.S.C. 316(a)(5), as
amended. These rules are procedural
and/or interpretive rules. See Bachow
Commc’ns Inc. v. F.C.C., 237 F.3d 683,
690 (D.C. Cir. 2001) (Rules governing an
application process are procedural
under the Administrative Procedure
Act.); Inova Alexandria Hosp. v.
Shalala, 244 F.3d 342, 350 (4th Cir.
2001) (Rules for handling appeals were
procedural where they did not change
the substantive requirements for
reviewing claims.); Nat’l Org. of
Veterans’ Advocates v. Sec’y of Veterans
Affairs, 260 F.3d 1365, 1375 (Fed. Cir.
2001) (Rule that clarifies interpretation
of a statute is interpretive.); JEM Broad.
Co. v. F.C.C., 22 F.3d 320, 328 (D.C. Cir.
1994) (Rules are not legislative because
they do not ‘‘foreclose effective
opportunity to make one’s case on the
merits.’’).
Accordingly, prior notice and
opportunity for public comment are not
required pursuant to 5 U.S.C. 553(b) or
(c) (or any other law). See Cooper Techs.
Co. v. Dudas, 536 F.3d 1330, 1336–37
(Fed. Cir. 2008) (stating that 5 U.S.C.
553, and thus 35 U.S.C. 2(b)(2)(B), do
not require notice and comment
rulemaking for ‘‘interpretative rules,
general statements of policy, or rules of
agency organization, procedure, or
practice’’ (quoting 5 U.S.C. 553(b)(A))).
However, the Office chose to seek
public comment before implementing
the rule to benefit from the public’s
input.
B. Regulatory Flexibility Act: As prior
notice and an opportunity for public
comment are not required pursuant to 5
U.S.C. 553 or any other law, neither a
regulatory flexibility analysis nor a
certification under the Regulatory
Flexibility Act (5 U.S.C. 601–612) is
required. See 5 U.S.C. 603. Nonetheless,
for the reasons set forth herein, the
Senior Counsel for Regulatory and
Legislative Affairs in the Office of
General Law of the USPTO has certified
E:\FR\FM\07NOR1.SGM
07NOR1
nshattuck on DSK9F9SC42PROD with RULES
51574
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
to the Chief Counsel for Advocacy of the
Small Business Administration that this
rule will not have a significant
economic impact on a substantial
number of small entities. See 5 U.S.C.
605(b). This rule revises the rules of
practice before PTAB to explicitly
recognize that communications between
non-attorney or foreign patent
practitioners and their clients that
pertain to authorized practice before the
USPTO or foreign patent offices are
privileged, and to define those persons
who may avail themselves of this
privilege. These changes are expected to
create no additional burden to those
practicing before the Board as this rule
merely clarifies rights and protections
for the practitioner and client and does
not impose a change in practice or
requirements. In fact, this rule may
produce a small benefit from a
reduction in uncertainty and mitigation
of discovery costs. For the above
reasons, the changes in this rule will not
have a significant economic impact on
a substantial number of small entities.
C. Executive Order 12866 (Regulatory
Planning and Review): This rulemaking
has been determined to be not
significant for purposes of Executive
Order 12866 (Sept. 30, 1993).
D. Executive Order 13563 (Improving
Regulation and Regulatory Review): The
Office has complied with Executive
Order 13563. Specifically, the Office
has, to the extent feasible and
applicable: (1) Made a reasoned
determination that the benefits justify
the costs of the rule; (2) tailored the rule
to impose the least burden on society
consistent with obtaining the regulatory
objectives; (3) selected a regulatory
approach that maximizes net benefits;
(4) specified performance objectives; (5)
identified and assessed available
alternatives; (6) involved the public in
an open exchange of information and
perspectives among experts in relevant
disciplines, affected stakeholders in the
private sector, and the public as a
whole, and provided on-line access to
the rulemaking docket; (7) attempted to
promote coordination, simplification,
and harmonization across government
agencies and identified goals designed
to promote innovation; (8) considered
approaches that reduce burdens and
maintain flexibility and freedom of
choice for the public; and (9) ensured
the objectivity of scientific and
technological information and
processes.
E. Executive Order 13771 (Reducing
Regulation and Controlling Regulatory
Costs): This rule is not an Executive
Order 13771 regulatory action because
this rule is not significant under
Executive Order 12866.
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
F. Executive Order 13132
(Federalism): This rulemaking does not
contain policies with federalism
implications sufficient to warrant
preparation of a Federalism Assessment
under Executive Order 13132 (Aug. 4,
1999).
G. Executive Order 13175 (Tribal
Consultation): This rulemaking will not:
(1) Have substantial direct effects on one
or more Indian tribes; (2) impose
substantial direct compliance costs on
Indian tribal governments; or (3)
preempt tribal law. Therefore, a tribal
summary impact statement is not
required under Executive Order 13175
(Nov. 6, 2000).
H. Executive Order 13211 (Energy
Effects): This rulemaking is not a
significant energy action under
Executive Order 13211 because this
rulemaking is not likely to have a
significant adverse effect on the supply,
distribution, or use of energy. Therefore,
a Statement of Energy Effects is not
required under Executive Order 13211
(May 18, 2001).
I. Executive Order 12988 (Civil Justice
Reform): This rulemaking meets
applicable standards to minimize
litigation, eliminate ambiguity, and
reduce burden as set forth in sections
3(a) and 3(b)(2) of Executive Order
12988 (Feb. 5, 1996).
J. Executive Order 13045 (Protection
of Children): This rulemaking does not
concern an environmental risk to health
or safety that may disproportionately
affect children under Executive Order
13045 (Apr. 21, 1997).
K. Executive Order 12630 (Taking of
Private Property): This rulemaking will
not affect a taking of private property or
otherwise have taking implications
under Executive Order 12630 (Mar. 15,
1988).
L. Congressional Review Act: Under
the Congressional Review Act
provisions of the Small Business
Regulatory Enforcement Fairness Act of
1996 (5 U.S.C. 801 et seq.), prior to
issuing any final rule, the United States
Patent and Trademark Office will
submit a report containing the rule and
other required information to the United
States Senate, the United States House
of Representatives, and the Comptroller
General of the Government
Accountability Office. The changes in
this final rule are not expected to result
in an annual effect on the economy of
100 million dollars or more, a major
increase in costs or prices, or significant
adverse effects on competition,
employment, investment, productivity,
innovation, or the ability of United
States-based enterprises to compete
with foreign-based enterprises in
domestic and export markets. Therefore,
PO 00000
Frm 00026
Fmt 4700
Sfmt 4700
this final rule is not a ‘‘major rule’’ as
defined in 5 U.S.C. 804(2).
M. Unfunded Mandates Reform Act of
1995: The changes set forth in this
rulemaking do not involve a Federal
intergovernmental mandate that will
result in the expenditure by State, local,
and tribal governments, in the aggregate,
of 100 million dollars (as adjusted) or
more in any one year, or a Federal
private sector mandate that will result
in the expenditure by the private sector
of 100 million dollars (as adjusted) or
more in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions are
necessary under the provisions of the
Unfunded Mandates Reform Act of
1995. See 2 U.S.C. 1501 et seq.
N. National Environmental Policy
Act: This rulemaking will not have any
effect on the quality of the environment
and is thus categorically excluded from
review under the National
Environmental Policy Act of 1969. See
42 U.S.C. 4321 et seq.
O. National Technology Transfer and
Advancement Act: The requirements of
section 12(d) of the National
Technology Transfer and Advancement
Act of 1995 (15 U.S.C. 272 note) are not
applicable because this rulemaking does
not contain provisions which involve
the use of technical standards.
P. Paperwork Reduction Act: The
Paperwork Reduction Act of 1995 (44
U.S.C. 3501–3549) requires that the
Office consider the impact of paperwork
and other information collection
burdens imposed on the public. This
final rule involves information
collection requirements which are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3549). This rulemaking
does not add any additional information
requirements or fees for parties before
the Board. Therefore, the Office is not
resubmitting information collection
packages to OMB for its review and
approval because the revisions in this
rulemaking do not materially change the
information collections approved under
OMB control number 0651–0069.
Notwithstanding any other provision
of law, no person is required to respond
to, nor shall any person be subject to, a
penalty for failure to comply with a
collection of information subject to the
requirements of the Paperwork
Reduction Act unless that collection of
information displays a currently valid
OMB control number.
List of Subjects in 37 CFR Part 42
Administrative practice and
procedure, Inventions and patents.
E:\FR\FM\07NOR1.SGM
07NOR1
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Rules and Regulations
For the reasons set forth in the
preamble, 37 CFR part 42 is amended as
follows.
PART 42—TRIAL PRACTICE BEFORE
THE PATENT TRIAL AND APPEAL
BOARD
2. Add § 42.57 to read as follows:
Privilege for patent practitioners.
nshattuck on DSK9F9SC42PROD with RULES
(a) Privileged communications. A
communication between a client and a
USPTO patent practitioner or a foreign
jurisdiction patent practitioner that is
reasonably necessary and incident to the
scope of the practitioner’s authority
shall receive the same protections of
privilege under Federal law as if that
communication were between a client
and an attorney authorized to practice
in the United States, including all
limitations and exceptions.
(b) Definitions. The term ‘‘USPTO
patent practitioner’’ means a person
who has fulfilled the requirements to
practice patent matters before the
United States Patent and Trademark
Office under § 11.7 of this chapter.
‘‘Foreign jurisdiction patent
practitioner’’ means a person who is
authorized to provide legal advice on
patent matters in a foreign jurisdiction,
provided that the jurisdiction
establishes professional qualifications
and the practitioner satisfies them. For
foreign jurisdiction practitioners, this
rule applies regardless of whether that
jurisdiction provides privilege or an
equivalent under its laws.
(c) Scope of coverage. USPTO patent
practitioners and foreign jurisdiction
patent practitioners shall receive the
same treatment as attorneys on all issues
affecting privilege or waiver, such as
communications with employees or
assistants of the practitioner and
communications between multiple
practitioners.
Joseph Matal,
Associate Solicitor, performing the functions
and duties of the Under Secretary of
Commerce for Intellectual Property and
Director of the United States Patent and
Trademark Office.
[FR Doc. 2017–24190 Filed 11–6–17; 8:45 am]
BILLING CODE 3510–16–P
VerDate Sep<11>2014
15:04 Nov 06, 2017
Jkt 244001
[EPA–R05–OAR–2017–0280; FRL–9969–89–
Region 5]
Environmental Protection
Agency (EPA).
ACTION: Direct final rule.
AGENCY:
Authority: 35 U.S.C. 2(b)(2), 6, 21, 23, 41,
135, 311, 312, 316, 321–326; Public Law 112–
29, 125 Stat. 284; and Pub. L. 112–274, 126
Stat. 2456.
§ 42.57
40 CFR Part 52
Air Plan Approval; Wisconsin; 2017
Revisions to NR 400 and 406
1. The authority citation for 37 CFR
part 42 continues to read as follows:
■
■
ENVIRONMENTAL PROTECTION
AGENCY
The Environmental Protection
Agency (EPA) is taking direct final
action to approve a revision to the
Wisconsin State Implementation Plan
(SIP) submitted by the Wisconsin
Department of Natural Resources
(WDNR) to EPA on May 16, 2017. The
revision replaces the definition of
‘‘emergency electric generator’’ with a
broader definition of ‘‘restricted internal
combustion engine’’. In addition, the
revision makes amendments to
procedures for revoking construction
permits as well as language changes and
other administrative updates. Lastly,
WDNR is removing from the SIP two
Wisconsin Administrative Code
provisions that affect eligibility of
coverage under general and construction
permits.
DATES: This direct final rule will be
effective January 8, 2018, unless EPA
receives adverse comments by
December 7, 2017. If adverse comments
are received, EPA will publish a timely
withdrawal of the direct final rule in the
Federal Register informing the public
that the rule will not take effect.
ADDRESSES: Submit your comments,
identified by Docket ID No. EPA–R05–
OAR–2017–0280 at https://
www.regulations.gov or via email to
damico.genevieve@epa.gov. For
comments submitted at Regulations.gov,
follow the online instructions for
submitting comments. Once submitted,
comments cannot be edited or removed
from Regulations.gov. For either manner
of submission, EPA may publish any
comment received to its public docket.
Do not submit electronically any
information you consider to be
Confidential Business Information (CBI)
or other information whose disclosure is
restricted by statute. Multimedia
submissions (audio, video, etc.) must be
accompanied by a written comment.
The written comment is considered the
official comment and should include
discussion of all points you wish to
make. EPA will generally not consider
comments or comment contents located
outside of the official comment (i.e. on
the web, cloud, or other file sharing
system). For additional submission
SUMMARY:
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
51575
methods, please contact the person
identified in the FOR FURTHER
INFORMATION CONTACT section. For the
full EPA public comment policy,
information about CBI or multimedia
submissions, and general guidance on
making effective comments, please visit
https://www2.epa.gov/dockets/
commenting-epa-dockets.
FOR FURTHER INFORMATION CONTACT:
Radhica Kanniganti, Environmental
Engineer, Air Permits Section, Air
Programs Branch (AR–18J),
Environmental Protection Agency,
Region 5, 77 West Jackson Boulevard,
Chicago, Illinois 60604, (312) 886–8097,
kanniganti.radhica@epa.gov.
SUPPLEMENTARY INFORMATION:
Throughout this document whenever
‘‘we,’’ ‘‘us,’’ or ‘‘our’’ is used, we mean
EPA. This supplementary information
section is arranged as follows:
I. Review of State Submittals
II. What action is EPA taking?
III. Incorporation by Reference
IV. Statutory and Executive Order Reviews
I. Review of State Submittals
This final rulemaking addresses the
May 16, 2017, WDNR submittal for SIP
revision, revising the rules in the
Wisconsin SIP to align them with
Federal requirements. WDNR’s
submittal includes changes to the term
‘‘electric generator’’, replacing it with
‘‘restricted internal combustion engine’’
as well as other minor language and
administrative changes. Specifically, NR
400.02(136m) replaces the existing
definition of emergency ‘‘electric
generator’’ with a broader definition of
‘‘restricted internal combustion engine’’
and NR 406.04(1)(w) amends the
exemption language for ‘‘emergency
electric generators’’, replacing it with
exemption for ‘‘restricted use
reciprocating internal combustion
engines’’. NR 406.08(1) and NR 406.10
involve minor changes to language, and
NR 406.11(1) amends procedures for
revoking construction permits. These
changes serve the purpose of aligning
the state and Federal regulations and are
consistent with the Federal program.
WDNR is also requesting the removal of
two provisions from the SIP. NR
406.16(2)(d) and NR 406.17(3)(e) affect
the eligibility of coverage under general
and registration construction permits
based on whether the project
constituted a Type 2 action under the
previous ch. NR 150. However, the
current ch. NR 150 was amended and no
longer defines or sets requirements for
Type 2 actions. Removing these
provisions from Wisconsin’s SIP
ensures consistency with Wisconsin
Environmental Protection Act (WEPA)
E:\FR\FM\07NOR1.SGM
07NOR1
Agencies
[Federal Register Volume 82, Number 214 (Tuesday, November 7, 2017)]
[Rules and Regulations]
[Pages 51570-51575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24190]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
37 CFR Part 42
[Docket No. PTO-P-2016-0029]
RIN 0651-AD10
Rule on Attorney-Client Privilege for Trials Before the Patent
Trial and Appeal Board
AGENCY: Patent Trial and Appeal Board, United States Patent and
Trademark Office, U.S. Department of Commerce.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This final rule on attorney-client privilege amends the
existing rules relating to the United States Patent and Trademark
Office (Office or USPTO) trial practice for inter partes review, post-
grant review, the transitional program for covered business method
patents, and derivation proceedings that implemented provisions of the
Leahy-Smith America Invents Act (``AIA'') providing for trials before
the Office.
DATES: This rule is effective on December 7, 2017.
FOR FURTHER INFORMATION CONTACT: Edward Elliott, Attorney Advisor, by
telephone at (571) 272-7024 or by email at edward.elliott@uspto.gov.
SUPPLEMENTARY INFORMATION:
Executive Summary: Purpose: This final rule clarifies situations
where privilege is recognized for communications between clients and
their domestic or foreign patent attorneys and patent agents.
Background
In February 2015, the USPTO held a roundtable and solicited
comments on attorney-client privilege issues. See Notice of Roundtable
and Request for Comments on Domestic and International Issues Related
to Privileged Communications Between Patent Practitioners and Their
Clients, 80 FR 3953 (Jan. 26, 2015). As part of that process, the USPTO
requested comments on whether communications between patent applicants
or owners with their U.S. patent agents or foreign patent practitioners
should be recognized as privileged to the same
[[Page 51571]]
extent as communications with U.S. patent attorneys. Respondents
unanimously supported a rule recognizing such privilege in courts. See
USPTO, Summary of Roundtable and Written Comments, available at https://www.uspto.gov/sites/default/files/documents/Summary%20of%20Privileged%20Communication%20Roundtable.pdf (``Privilege
Report'').
Some roundtable participants noted that rules regarding privilege
for U.S. patent agents and foreign practitioners in PTAB discovery
proceedings were difficult to discern, as there has been no explicit
rule on privilege. When the issue arises before PTAB, Administrative
Law Judges make legal determinations as to which communications may be
protected from disclosure on a case-by-case basis, based on the Federal
Rules of Evidence and common law. See 37 CFR 42.62(a); see also GEA
Process Engineering, Inc. v. Steuben Foods, Inc., IPR2014-00041, Paper
117 (PTAB 2014). U.S. courts have devised several different approaches
to determine under what circumstances communications with these
practitioners are privileged. As the Privilege Report notes, the common
law on privilege for domestic and foreign patent practitioners varies
across jurisdictions. Different approaches are taken, and results
sometimes conflict. This may lead to administrative inefficiencies and
inconsistencies in outcomes, as PTAB must select which set of common
law rules to follow.
Administrative Law Judges in other agencies have treated certain
confidential communications with a patent agent as privileged. See,
e.g., USITC Inv. No. 337-TA-339, slip op. at 2, 1992 WL 811804 (ITC
1992) (finding that confidential communications between a U.S. patent
agent and his client in connection with a patent prosecution are
privileged). In 2016, the Federal Circuit recognized that attorney-
client privilege applies to U.S. patent agents acting within the scope
of their authorized practice. See In re Queen's University at Kingston,
820 F.3d 1287 (Fed. Cir. 2016).
To address the aforementioned issues with privilege rules, the
USPTO put forth a proposed PTAB rule for public comment in October
2016. See Rule Recognizing Privileged Communications Between Clients
and Patent Practitioners at the Patent Trial and Appeal Board, 81 FR
71653 (Oct. 18, 2016). The Office received eighteen comments from bar
associations, trade groups, law firms, and individuals. The Office
expresses its gratitude for the thoughtful and comprehensive comments
provided by the public, which are available online at https://www.regulations.gov/docket?D=PTO-P-2016-0029.
The vast majority of commenters expressed support for this rule,
echoing the need for clarity and certainty in this area. The policy
arguments they raised in favor are already covered extensively in the
Privilege Report. Several commenters raised additional issues about
specific language in the proposed rule, which are addressed herein. A
few commenters opposed the rule based on misunderstandings of the scope
and purpose of the rule, which are clarified herein as well. Based on
the feedback, the Office presents the following final rule on
recognizing privilege for patent attorneys and agents.
Responses to Comments
Nature of Privilege
Comments: Some comments expressed concern over the scope and
interpretation of the proposed rule. One commenter objected to
expanding those eligible to practice before PTAB to include agents.
Others characterized the rule as primarily to protect communications
between clients and counsel involved in PTAB proceedings.
Response: Attorney-client privilege exists to protect clients. It
allows them to have full and frank discussions with attorneys when
seeking legal advice, without fear that those discussions will be used
against them in legal proceedings. The privilege vests with the client,
not the attorney, and does not confer authorization to practice law,
but rather flows from those already having such authorization. Because
of this, recognizing privilege for patent agents does not determine
what types of work they are authorized to perform. The authorized
functions of patents agents, including representing clients before
PTAB, are established in 37 CFR 11.5(b). Likewise, privilege does not
confer additional power to patent agents because it vests in the
client, not the agent or attorney. Applying the privilege to agents
simply recognizes that they perform legal services and that clients
deserve the same protections regardless of which type of authorized
legal provider they choose. Further, some foreign jurisdictions rely
entirely or almost entirely on non-attorney patent agents. In such
jurisdictions, hiring an attorney to handle patent matters can be
difficult or impossible. See the Privilege Report for further
discussion of the policy considerations supporting privilege for patent
agents.
More fundamentally, this rule is not intended primarily to protect
communications between clients and their counsel for purposes of PTAB
proceedings. Rather, it is primarily intended to protect communications
made when seeking patents at the USPTO or foreign IP offices, such as
when prosecuting applications or contemplating whether to file. The
counsel on those communications may not be involved in any PTAB
proceedings. Communications about prosecution are much more commonly
implicated in PTAB discovery proceedings than communications about the
PTAB proceeding itself. Perhaps this reflects the inherent asymmetry of
privilege protections: Both parties are affected if their
communications seeking legal advice about the PTAB proceeding are
discoverable, whereas only the patent holder is affected by discovery
of communications from prosecution. Regardless, the purpose of the rule
is to protect any communications with authorized counsel from discovery
in PTAB, not just communications about the instant proceeding.
Similarly, this privilege rule does not affect an attorney, agent,
or applicant's duty to disclose material information to the USPTO at
any time, as the duty of disclosure under 37 CFR 1.56 continues to be
controlling. This duty is not at odds with privilege protections; the
duty of disclosure governs all information known by a party and
establishes whether information must be provided to the USPTO, while
privilege governs material available to third party adversaries in
adjudicated proceedings under part 42. For instance, the privilege rule
does not apply in the filing and prosecution of a patent application.
Further, the privilege only protects information exchanged for purposes
of obtaining legal opinions or services, not underlying facts or
business documents. The precise metes and bounds of what types of
communications are protected by privilege are determined according to
Federal law. Finally, this rule does not nullify privilege for others
who are not covered by the rule, such as attorneys not admitted to
practice before the USPTO or a foreign patent office. Other sources of
privilege under Federal law remain unaffected.
Scope of Activities
Comments: Some commenters requested clarity on the scope of covered
activities. One commenter asked the USPTO to clarify whether a
communication with a registered patent agent about claim interpretation
of an issued patent would qualify as privileged. Others asked for
general clarification of what activities by patent agents would be
covered, with one
[[Page 51572]]
requesting examples of activities that would qualify for the privilege.
One commenter noted that 37 CFR 11.5(b)(1) may not provide an
exhaustive list of authorized activities.
Response: We understand the commenters' desire for clarity on these
issues. The USPTO has described the functions agents are authorized to
perform before the Office in 37 CFR 11.5(b)(1). Whether a particular
scenario falls within the bounds of an agent's authorization is subject
to determination by an appropriate authority.
More precisely defining what types of work patent agents are and
are not authorized to perform is a much larger issue that goes far
beyond privilege considerations. This rulemaking is not the proper
forum to address that issue. If the public feels that the general
definition of authorized functions put forth by the USPTO in Sec.
11.5(b)(1) should be updated, they should contact the USPTO to express
interest in a more comprehensive process to consider that issue, which
accounts for the numerous equities involved. We also note that
regardless of any clarifications made to the scope of authorized duties
for U.S. patent agents, the USPTO cannot alter or clarify the
authorized functions of foreign patent agents in their home
jurisdiction, which are established by foreign laws and regulations.
Federal Privilege
Comments: One comment suggested clarifying that the ``same
protections of privilege'' refers to Federal privilege, since state
courts have their own separate sources of privilege.
Response: We concur and have adjusted the rule to specify
``privilege under Federal law'' in paragraph (a).
Direct Communications
Comments: One comment suggested that the rule as written may only
cover communications directly between a client and a foreign
practitioner, and not communications made by the client's U.S. attorney
with the foreign practitioner. According to the comment, communications
made between a client's representatives in the absence of the client
could be inadvertently excluded by the current phrasing of the rule.
Response: Under U.S. Federal law, attorney-client privilege
generally encompasses communications with an attorney made by the
client's representatives as well as the client. Similarly, privilege
generally encompasses communications made with an attorney's employee
or assistant, as well as communications between multiple attorneys
working for a client. That is not to say such communications are
necessarily privileged; they must still meet the other requirements for
privilege, such as appropriate subject matter. However, these parties
are generally regarded as parties that fall within the scope of
privilege, rather than as third parties who break privilege.
Under the new rule, communications with such parties should
similarly be entitled to privilege under the same circumstances as when
the practitioner is an attorney. However, we recognize that there is
potential for a narrower reading of the proposed rule that does not
cover communications with such parties and therefore affords lesser
protection to non-attorney practitioners. We have added paragraph (c)
to the rule to clarify that the scope of coverage will be the same for
practitioners as for attorneys under these types of scenarios and any
other situations. For instance, privilege will extend to communications
with the aforementioned parties under appropriate circumstances, not
just to communications directly between the practitioner and the
client.
Limitations and Exceptions
Comments: One comment suggested explicitly defining which
``limitations and exceptions'' should apply to the privilege.
Response: Exceptions to attorney-client privilege such as crime/
fraud are based on longstanding common law, which continues to evolve.
Our purpose here is not to redefine those exceptions. This may lead to
growing discrepancies as the common law changes, which could lead to
disparate treatment of privilege for patent attorneys and agents
compared with other attorneys. Rather, this rule codifies who is
eligible for the privilege, while leaving questions about exceptions
and limitations for general jurisprudence to address in a broader
manner.
Practitioners With Limited Recognition
Comments: A couple of commenters noted that the rule does not
extend to all categories of practitioners, namely, those granted
limited recognition under 37 CFR 11.9.
Response: The rule has been amended to cover USPTO practitioners
meeting the registration requirements of 37 CFR 11.7. This includes
practitioners under both Sec. Sec. 11.6 and 11.9(b), who have
demonstrated the requisite legal, scientific, and technical
qualifications and moral character. Foreign practitioners practicing at
the USPTO under Sec. 11.9(c) can qualify for privilege under paragraph
(b) of the new rule through their admittance to practice in a foreign
jurisdiction. Students in the USPTO law school clinic program
practicing under Sec. 11.16 can qualify for privilege under paragraph
(c) of the new rule since they work under the supervision of a
registered practitioner. At this time, we are not convinced an
extension to other categories of practitioners is necessary or
appropriate. It is not clear that recognizing privilege for these
individuals furthers any of the policy reasons for applying privilege
to patent agents, or that these individuals play a significant role in
providing legal services for applicants.
Relation to In re Queen's
Comments: A few commenters noted the parallels between this rule
and the Federal Circuit's decision in In re Queen's University,
wondering if a USPTO rule is still necessary and whether there would be
any distinction between our rule and the Federal Circuit's. One
commenter mentioned a supposed difference in coverage for third-party
patent validity opinions by agents.
Response: The USPTO supports the Federal Circuit's finding of
privilege for patent agents as a matter of public policy. The Privilege
Report catalogs the many reasons that privilege for patent agents is
warranted. A USPTO rule on privilege is still needed, for at least
several reasons. The Queen's decision was a 2-1 panel result, which may
be revisited in future cases either en banc at the Federal Circuit or
at the Supreme Court. There are clarity benefits to having a rule
explicitly codified rather than only in common law.
Also, the Federal Circuit decision only addresses domestic patent
agents, not foreign attorneys and agents. Without comparable
protections in U.S. tribunals for foreign practitioners, privileged
communications with U.S. patent attorneys may effectively lose that
protection through parallel communications with foreign practitioners
prosecuting corresponding foreign applications, which often raise very
similar legal issues. Having a U.S. attorney supervise communications
with foreign practitioners is not only an undesirable policy, but may
not be enough to preserve privilege in all circumstances. Because the
U.S. attorney is generally not authorized to practice law in foreign
jurisdictions, the foreign attorney might not be considered as working
``under the supervision'' of the U.S. attorney in all instances.
Further, some jurisdictions use non-attorney patent agents exclusively
or predominantly, so it may not be possible for applicants to rely on
[[Page 51573]]
privilege afforded by U.S. courts to foreign attorneys. The new
privilege rule protects eligible communications with qualified foreign
attorneys and agents from discovery at PTAB, preventing such back door
exposure. The rule does not have extraterritorial effects; how
communications with U.S. and foreign practitioners are treated by
foreign courts is entirely up to the foreign jurisdiction.
Another reason for the USPTO's rule is administrative economy and
judicial efficiency, as explained by commenter John Cross of the
University of Louisville. The typical approach to privilege for foreign
practitioners examines whether the foreign jurisdiction affords
something like privilege for attorneys and agents. However, this
inquiry can be intensive, difficult, and lead to inconsistent results,
because many jurisdictions do not need a comparable protection when
their constrained discovery system prevents communications with patent
practitioners from even being discoverable. Similarly, U.S. courts that
use a ``touch base'' standard often make complex inquiries into a
foreign communication's nexus with the United States, which can lead to
uncertain and inconsistent results. The USPTO rule simplifies such
inquiries by instead considering whether the foreign practitioner was
authorized to practice within their home jurisdiction by satisfying
their jurisdiction's professional requirements, and whether the
communications fall within their authorized scope of practice in that
jurisdiction. These criteria are simpler to adjudicate and lead to more
predictable and consistent results, helping applicants understand where
privilege applies long before they appear at a tribunal.
Also, the USPTO rule applies regardless of the source of privilege
for agents. Whether there is a separate agent-client privilege or
agents are afforded attorney-client privilege on the basis of
practicing patent law does not matter for purposes of this rule. The
rule simply recognizes that privilege issues will be treated the same
for agents as for attorneys within their scope of authorized practice.
Practice of Law
Comments: Two commenters suggested that the rule would promote the
``unauthorized practice of law'' by U.S. patent agents. It was
suggested that participation by patent agents in PTAB proceedings would
constitute unauthorized practice, and that agents participating in PTAB
proceedings held concurrently with patent litigation on the same
patents would constitute unauthorized litigation practice by those
agents. One of these commenters also said that state bar rules may
conflict with this PTAB rule.
Response: As previously mentioned, the rule does not grant
additional powers to patent agents. Privilege is a protection that
vests with the client, not the practitioner. Agents are already
authorized to practice before PTAB in any USPTO proceedings. Practice
before PTAB cannot be unauthorized practice of law because U.S. patent
agents are authorized to do so.
The second objection suggests that practicing before PTAB is
tantamount to practicing before Federal courts when there is concurrent
litigation on the same patents. Because they are separate venues with
separate practices and practitioners, this argument is not persuasive.
Agents are authorized to advise and represent clients in PTAB
proceedings because the issues are restricted to patent law matters
they are authorized to perform. Federal courts have different
jurisdiction than PTAB and consider a range of non-patent issues. The
fact that certain patent issues, such as validity, may arise before
both tribunals does not equate practice before both venues. Just
because a practitioner is authorized to address the issue in one forum
does not mean they are authorized to address it in other forums. This
is true regardless of whether the practitioner is an agent or an
attorney and whether the two forums are, for instance, PTAB and a
Federal court, or a Federal court and a foreign court.
Finally, state bar rules generally are not germane to USPTO rules.
The USPTO may properly regulate the conduct of practitioners before the
Office, including PTAB proceedings, as authorized by Congress.
Similarly, states can properly regulate the practice of law within
their borders, subject to federalism principles and rules established
by the Supreme Court. The USPTO and states have separate jurisdiction.
States may of course consider the policy issues the USPTO has
documented when deciding privilege matters within their own courts for
domestic and foreign patent agents and attorneys.
Changes From the Proposed Rule
In response to comments received from the public, the USPTO makes
the following changes from the proposed rule. The terms for types of
practitioners (domestic and foreign) were adjusted slightly for
uniformity with other rules. The application of Federal law was
clarified. The USPTO registration requirement now points to 37 CFR 11.7
for more precision. Paragraph (c) was added to clarify that non-
attorney practitioners are afforded privilege in all the same
situations as attorneys, not just for direct communications between
practitioner and client.
Rulemaking Considerations
A. Administrative Procedure Act (APA): This final rule revises the
rules relating to Office trial practice for inter partes review, post-
grant review, the transitional program for covered business method
patents, and derivation proceedings. The changes being adopted in this
notice do not change the substantive criteria of patentability. These
changes involve rules of agency practice. See, e.g., 35 U.S.C.
316(a)(5), as amended. These rules are procedural and/or interpretive
rules. See Bachow Commc'ns Inc. v. F.C.C., 237 F.3d 683, 690 (D.C. Cir.
2001) (Rules governing an application process are procedural under the
Administrative Procedure Act.); Inova Alexandria Hosp. v. Shalala, 244
F.3d 342, 350 (4th Cir. 2001) (Rules for handling appeals were
procedural where they did not change the substantive requirements for
reviewing claims.); Nat'l Org. of Veterans' Advocates v. Sec'y of
Veterans Affairs, 260 F.3d 1365, 1375 (Fed. Cir. 2001) (Rule that
clarifies interpretation of a statute is interpretive.); JEM Broad. Co.
v. F.C.C., 22 F.3d 320, 328 (D.C. Cir. 1994) (Rules are not legislative
because they do not ``foreclose effective opportunity to make one's
case on the merits.'').
Accordingly, prior notice and opportunity for public comment are
not required pursuant to 5 U.S.C. 553(b) or (c) (or any other law). See
Cooper Techs. Co. v. Dudas, 536 F.3d 1330, 1336-37 (Fed. Cir. 2008)
(stating that 5 U.S.C. 553, and thus 35 U.S.C. 2(b)(2)(B), do not
require notice and comment rulemaking for ``interpretative rules,
general statements of policy, or rules of agency organization,
procedure, or practice'' (quoting 5 U.S.C. 553(b)(A))). However, the
Office chose to seek public comment before implementing the rule to
benefit from the public's input.
B. Regulatory Flexibility Act: As prior notice and an opportunity
for public comment are not required pursuant to 5 U.S.C. 553 or any
other law, neither a regulatory flexibility analysis nor a
certification under the Regulatory Flexibility Act (5 U.S.C. 601-612)
is required. See 5 U.S.C. 603. Nonetheless, for the reasons set forth
herein, the Senior Counsel for Regulatory and Legislative Affairs in
the Office of General Law of the USPTO has certified
[[Page 51574]]
to the Chief Counsel for Advocacy of the Small Business Administration
that this rule will not have a significant economic impact on a
substantial number of small entities. See 5 U.S.C. 605(b). This rule
revises the rules of practice before PTAB to explicitly recognize that
communications between non-attorney or foreign patent practitioners and
their clients that pertain to authorized practice before the USPTO or
foreign patent offices are privileged, and to define those persons who
may avail themselves of this privilege. These changes are expected to
create no additional burden to those practicing before the Board as
this rule merely clarifies rights and protections for the practitioner
and client and does not impose a change in practice or requirements. In
fact, this rule may produce a small benefit from a reduction in
uncertainty and mitigation of discovery costs. For the above reasons,
the changes in this rule will not have a significant economic impact on
a substantial number of small entities.
C. Executive Order 12866 (Regulatory Planning and Review): This
rulemaking has been determined to be not significant for purposes of
Executive Order 12866 (Sept. 30, 1993).
D. Executive Order 13563 (Improving Regulation and Regulatory
Review): The Office has complied with Executive Order 13563.
Specifically, the Office has, to the extent feasible and applicable:
(1) Made a reasoned determination that the benefits justify the costs
of the rule; (2) tailored the rule to impose the least burden on
society consistent with obtaining the regulatory objectives; (3)
selected a regulatory approach that maximizes net benefits; (4)
specified performance objectives; (5) identified and assessed available
alternatives; (6) involved the public in an open exchange of
information and perspectives among experts in relevant disciplines,
affected stakeholders in the private sector, and the public as a whole,
and provided on-line access to the rulemaking docket; (7) attempted to
promote coordination, simplification, and harmonization across
government agencies and identified goals designed to promote
innovation; (8) considered approaches that reduce burdens and maintain
flexibility and freedom of choice for the public; and (9) ensured the
objectivity of scientific and technological information and processes.
E. Executive Order 13771 (Reducing Regulation and Controlling
Regulatory Costs): This rule is not an Executive Order 13771 regulatory
action because this rule is not significant under Executive Order
12866.
F. Executive Order 13132 (Federalism): This rulemaking does not
contain policies with federalism implications sufficient to warrant
preparation of a Federalism Assessment under Executive Order 13132
(Aug. 4, 1999).
G. Executive Order 13175 (Tribal Consultation): This rulemaking
will not: (1) Have substantial direct effects on one or more Indian
tribes; (2) impose substantial direct compliance costs on Indian tribal
governments; or (3) preempt tribal law. Therefore, a tribal summary
impact statement is not required under Executive Order 13175 (Nov. 6,
2000).
H. Executive Order 13211 (Energy Effects): This rulemaking is not a
significant energy action under Executive Order 13211 because this
rulemaking is not likely to have a significant adverse effect on the
supply, distribution, or use of energy. Therefore, a Statement of
Energy Effects is not required under Executive Order 13211 (May 18,
2001).
I. Executive Order 12988 (Civil Justice Reform): This rulemaking
meets applicable standards to minimize litigation, eliminate ambiguity,
and reduce burden as set forth in sections 3(a) and 3(b)(2) of
Executive Order 12988 (Feb. 5, 1996).
J. Executive Order 13045 (Protection of Children): This rulemaking
does not concern an environmental risk to health or safety that may
disproportionately affect children under Executive Order 13045 (Apr.
21, 1997).
K. Executive Order 12630 (Taking of Private Property): This
rulemaking will not affect a taking of private property or otherwise
have taking implications under Executive Order 12630 (Mar. 15, 1988).
L. Congressional Review Act: Under the Congressional Review Act
provisions of the Small Business Regulatory Enforcement Fairness Act of
1996 (5 U.S.C. 801 et seq.), prior to issuing any final rule, the
United States Patent and Trademark Office will submit a report
containing the rule and other required information to the United States
Senate, the United States House of Representatives, and the Comptroller
General of the Government Accountability Office. The changes in this
final rule are not expected to result in an annual effect on the
economy of 100 million dollars or more, a major increase in costs or
prices, or significant adverse effects on competition, employment,
investment, productivity, innovation, or the ability of United States-
based enterprises to compete with foreign-based enterprises in domestic
and export markets. Therefore, this final rule is not a ``major rule''
as defined in 5 U.S.C. 804(2).
M. Unfunded Mandates Reform Act of 1995: The changes set forth in
this rulemaking do not involve a Federal intergovernmental mandate that
will result in the expenditure by State, local, and tribal governments,
in the aggregate, of 100 million dollars (as adjusted) or more in any
one year, or a Federal private sector mandate that will result in the
expenditure by the private sector of 100 million dollars (as adjusted)
or more in any one year, and will not significantly or uniquely affect
small governments. Therefore, no actions are necessary under the
provisions of the Unfunded Mandates Reform Act of 1995. See 2 U.S.C.
1501 et seq.
N. National Environmental Policy Act: This rulemaking will not have
any effect on the quality of the environment and is thus categorically
excluded from review under the National Environmental Policy Act of
1969. See 42 U.S.C. 4321 et seq.
O. National Technology Transfer and Advancement Act: The
requirements of section 12(d) of the National Technology Transfer and
Advancement Act of 1995 (15 U.S.C. 272 note) are not applicable because
this rulemaking does not contain provisions which involve the use of
technical standards.
P. Paperwork Reduction Act: The Paperwork Reduction Act of 1995 (44
U.S.C. 3501-3549) requires that the Office consider the impact of
paperwork and other information collection burdens imposed on the
public. This final rule involves information collection requirements
which are subject to review by the Office of Management and Budget
(OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3549).
This rulemaking does not add any additional information requirements or
fees for parties before the Board. Therefore, the Office is not
resubmitting information collection packages to OMB for its review and
approval because the revisions in this rulemaking do not materially
change the information collections approved under OMB control number
0651-0069.
Notwithstanding any other provision of law, no person is required
to respond to, nor shall any person be subject to, a penalty for
failure to comply with a collection of information subject to the
requirements of the Paperwork Reduction Act unless that collection of
information displays a currently valid OMB control number.
List of Subjects in 37 CFR Part 42
Administrative practice and procedure, Inventions and patents.
[[Page 51575]]
For the reasons set forth in the preamble, 37 CFR part 42 is
amended as follows.
PART 42--TRIAL PRACTICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
0
1. The authority citation for 37 CFR part 42 continues to read as
follows:
Authority: 35 U.S.C. 2(b)(2), 6, 21, 23, 41, 135, 311, 312, 316,
321-326; Public Law 112-29, 125 Stat. 284; and Pub. L. 112-274, 126
Stat. 2456.
0
2. Add Sec. 42.57 to read as follows:
Sec. 42.57 Privilege for patent practitioners.
(a) Privileged communications. A communication between a client and
a USPTO patent practitioner or a foreign jurisdiction patent
practitioner that is reasonably necessary and incident to the scope of
the practitioner's authority shall receive the same protections of
privilege under Federal law as if that communication were between a
client and an attorney authorized to practice in the United States,
including all limitations and exceptions.
(b) Definitions. The term ``USPTO patent practitioner'' means a
person who has fulfilled the requirements to practice patent matters
before the United States Patent and Trademark Office under Sec. 11.7
of this chapter. ``Foreign jurisdiction patent practitioner'' means a
person who is authorized to provide legal advice on patent matters in a
foreign jurisdiction, provided that the jurisdiction establishes
professional qualifications and the practitioner satisfies them. For
foreign jurisdiction practitioners, this rule applies regardless of
whether that jurisdiction provides privilege or an equivalent under its
laws.
(c) Scope of coverage. USPTO patent practitioners and foreign
jurisdiction patent practitioners shall receive the same treatment as
attorneys on all issues affecting privilege or waiver, such as
communications with employees or assistants of the practitioner and
communications between multiple practitioners.
Joseph Matal,
Associate Solicitor, performing the functions and duties of the Under
Secretary of Commerce for Intellectual Property and Director of the
United States Patent and Trademark Office.
[FR Doc. 2017-24190 Filed 11-6-17; 8:45 am]
BILLING CODE 3510-16-P